What is the price-to-earnings ratio of AnaptysBio?
The price-earnings ratio of AnaptysBio is currently 19.3.
AnaptysBio P/S 2024
AnaptysBio P/S
19.3
Ticker
ANAB
ISIN
US0327241065
WKN
A2AJ8C
As of Oct 6, 2024, AnaptysBio's P/S ratio stood at 19.3, a -33.45% change from the 29 P/S ratio recorded in the previous year.
The AnaptysBio P/S history
AnaptysBio Aktienanalyse
What does AnaptysBio do?
AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding AnaptysBio's P/S Ratio
AnaptysBio's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing AnaptysBio's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating AnaptysBio's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in AnaptysBio’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about AnaptysBio stock
How has the price-earnings ratio of AnaptysBio changed compared to last year?
The price-to-earnings ratio of AnaptysBio has increased by -33.45% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of AnaptysBio high compared to other companies?
Yes, the price-to-earnings ratio of AnaptysBio is high compared to other companies.
How does an increase in the price-earnings ratio of AnaptysBio affect the company?
An increase in the price-earnings ratio of AnaptysBio would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of AnaptysBio affect the company?
A decrease in the price-earnings ratio of AnaptysBio would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of AnaptysBio?
Some factors that influence the price-earnings ratio of AnaptysBio are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does AnaptysBio pay?
Over the past 12 months, AnaptysBio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnaptysBio is expected to pay a dividend of 0 USD.
What is the dividend yield of AnaptysBio?
The current dividend yield of AnaptysBio is .
When does AnaptysBio pay dividends?
AnaptysBio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnaptysBio?
AnaptysBio paid dividends every year for the past 0 years.
What is the dividend of AnaptysBio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnaptysBio located?
AnaptysBio is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnaptysBio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnaptysBio from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did AnaptysBio pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of AnaptysBio in the year 2023?
In the year 2023, AnaptysBio distributed 0 USD as dividends.
In which currency does AnaptysBio pay out the dividend?
The dividends of AnaptysBio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnaptysBio
Our stock analysis for AnaptysBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnaptysBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
